Table 1.
Description of publicly available proteomic studies used in the secretome meta-analysis.
| Ref. | Cell Line /Tumor Tissue | Labeling | Technique | Validation Method |
|---|---|---|---|---|
| [37] | Panc1 | Silac | LC-MS/MS | WB, IHC, MA |
| [43] | AsPC1, MiaPaCa2, Panc1 | Free | LC-MS/MS | - |
| [41] | Panc1 | iTRAQ | LC-MS/MS | WB, ELISA |
| [45] | Paca44, Panc1, BxPc3, MiaPaca2, HPSC, A818-4 | Free | LC-MS/MS | - |
| [46] | BxPC-3, MIA PaCa-2, Panc1, AsPC-1 | Free | LC-MS/MS | WB, IHC, ELISA |
| [93] | CAPAN-2, RLT-PSC | Silac | LC-MRM/MS | - |
| [47] | PC-1.0, PC-1 (Hamster) | Silac | Nano-RPLC-MS/MS | WB |
| [49] | BxPC3, MiaPaca2, Panc1 | Free | ESI-MS/MS | WB |
| [50] | SOJ-6, BxPC-3, MiaPaCa-2, Panc-1 | Free | MALDI-TOF MS | WB |
| [34] | PAN02 (Mouse) | Free | MS/MS | ELISA |
| [51] | NIT-1 | Free | MS/MS | WB |
| [52] | Panc-1 | Free | LC-MS/MS | - |
| [53] | MiaPaCa-2, BxPc-3, Panc-1, AsPc-1 | Free | MALDI–TOF MS | WB |
| [54] | Adenocarcinoma tissue | Free | LC-MS/MS | WB |
| [55] | BON-1, NCI-H727, SHP-77 | Free | LC-MS/MS | WB |
| [3] | BxPc3, MIA-PaCa2, Panc1, CAPAN1, CFPAC1, SU.86.86, HPDE, PJ | Free | LC-MS/MS | ELISA |
| [56] | KLM, PK-59, MIAPaCa2 | Free | MS/MS | WB |
| [57] | Panc-1, SW1990 | iTRAQ | LC-MS/MS | - |
| [58] | MIA PaCa-2 | labeling | MALDI-TOF MS | WB |
| [59] | CAPAN-2 | Silac | LC-MS/MS | IHC |
Ref.: reference; Rodent cell lines are specified in parentheses; Silac: Stable isotope labeling with amino acids in cell culture; iTRAQ: Isobaric tags for relative and absolute quantitation; LC-MS/MS: Liquid chromatography-tandem mass spectrometry; LC-MRM/MS: Multiplexed liquid chromatography multiple-reaction-monitoring mass spectrometry; Nano-RPLC-MS/MS: Nanoscale liquid chromatography coupled to tandem mass spectrometry; ESI-MS/MS: Electrospray ionization mass spectrometry; MALDI-TOF MS: Laser desorption ionization-time of flight mass spectrometry; MS/MS: Tandem mass spectrometry, PJ: Pancreatic juice; WB: Western Blot; IHC: Immunohistochemistry; MA: Microarrays.